BG
BeiGene
BGNE·NASDAQBeijing CNFounded 201010,500 employees
Large CapbiotechPublicOncologyHematology
Platform: Zanubrutinib
Market Cap
$22B
All Drugs
7
Clinical Trials
13
Failed / Terminated
1
FDA Approved
2
Stock Price & Catalysts (BGNE)
Loading BGNE stock data...
Drug Pipeline (7 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| BGN-6990 | BGN-6990 | Phase 2/3 | 1 | BCMA | NarcolepsyCLL | ||
| Adagracapivasertib | BGN-3861 | NDA/BLA | 1 | BET | GAParkinson's | ||
| Semazasiran | BGN-7569 | Phase 1 | 2 | PD-1 | NMOSD | ||
| BGN-8936 | BGN-8936 | Phase 1/2 | 2 | FXIa | AngelmanSMA | ||
| BGN-3859 | BGN-3859 | Approved | 1 | PSMA | ALSMyelofibrosis | ||
| Pemitapinarof | BGN-6777 | Approved | 4 | KRASG12C | NBFTD | ||
| BGN-3305 | BGN-3305 | Phase 2 | 2 | BCMA | Parkinson'sPsA |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (13)